Results 41 to 50 of about 79,407 (254)

Tenofovir Alafenamide Fumarate Reduces Virological Replication in HBeAg-Negative Patients With Normal Alanine Aminotransferase: A 48-Week Randomised Controlled Trial. [PDF]

J Viral Hepat
ABSTRACT The optimal strategy for chronic hepatitis B virus (HBV) infected patients with negative hepatitis B e‐antigen (HBeAg) and normal alanine aminotransferase (ALT) remains uncertain. This study aimed to evaluate the safety and efficacy of tenofovir alafenamide fumarate (TAF) treatment in this patient population.
Luo Q, Xu W, Zhang Y, Li X, Lai J, Li J, Zheng X, Deng H, Chen L, Zhu X, Xie C, Peng L.   +11 more
europepmc   +2 more sources

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 [PDF]

, 2019
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic ...
Ajana, F, Arribas, JR, Bailey, J, Benson, P, Berenguer, J, Bhatti, L, Blaxhult, A, Brar, I, Bredeek, UF, Brinson, C, Brown, Kimberley, Brunetta, J, Casado, J, Clarke, A, Conway, B, Cotte, L, Crofoot, G, Cunningham, D, Cunningham, Douglas, de Vente, J, De Wit, S, De Wit, Stéphane, DeJesus, E, Dietz, C, Dretler, R, Eron, J, Eron, Joseph J, Fehr, J, Felizarta, F, Fichtenbaum, C, Flamholc, L, Florence, E, Galindo, MJ, Gallant, J, Gasiorowski, J, Gatell, JM, Gathe, J, Gazzard, BG, Girardy, P-M, Gisslèn, M, Gutierrez, F, Gutierrez, MDM, Hagins, D, Halota, W, Henn, S, Henry, WK, Horban, A, Hufkens, Veerle, Huhn, G, Iribarren, JA, Jain, M, Jezorwski, John, Johnson, MA, Katlama, C, Klein, M, Knobel, H, Lathouwers, Erkki, Lucasti, C, Martorell, C, McDonald, C, Mills, A, Molina, J-M, Morales-Ramirez, J, Mounzer, K, Moutschen, M, Murphy, D, Nahass, R, Negredo, E, Olivet, H, Opsomer, Magda, Orkin, C, Orkin, Chloe, Osiyemi, O, Perez-Valero, I, Petrovic, Romana, Piekarska, A, Pineda, JA, Podzamczer, D, Poizot-Martin, I, Portilla Sogorb, J, Post, F, Post, Frank A, Prelutsky, D, Pulido, F, Pulido, Federico, Rachlis, A, Raffi, F, Ramgopal, M, Rashbaum, B, Rauch, A, Rey, D, Reynes, J, Ricart, C, Richmond, G, Rivero, A, Ruane, P, Santos Gil, I, Scarsella, A, Scribner, A, Shafran, S, Shalit, P, Shamblaw, D, Slim, J, Stoeckle, M, Tashima, K, Teicher, E, Thalme, A, Ustianowski, A, Van Landuyt, Erika, Van Wijngaerden, E, Vandekerckhove, Linos, Vandercam, B, Voskuhl, G, Walmsley, S, Ward, D, Waters, L, Wilkin, A, Witor, A, Yazdanpanah, Y   +118 more
core   +2 more sources

Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles

Nature Communications, 2021
Treatment and prevention of human immunodeficiency virus type one (HIV-1) infection was transformed through widespread use of antiretroviral therapy (ART). However, ART has limitations in requiring life-long daily adherence.
Denise A. Cobb, Nathan A Smith, S. Deodhar, Aditya N. Bade, N. Gautam, B. L. D. Shetty, J. McMillan, Y. Alnouti, S. Cohen, H. Gendelman, Benson J. Edagwa   +10 more
semanticscholar   +1 more source

Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications [PDF]

, 2015
One-fourth of individuals diagnosed with the human immunodeficiency virus concomitantly have the hepatitis C virus infection. Since the discovery of highly active antiretroviral therapy, liver complications have become the leading cause of morbidity and ...
Gandhi, Mona A., Kaur, Kirpal, Slish, Judianne   +2 more
core   +2 more sources

Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study

JAMA Oncology, 2019
Importance Entecavir and tenofovir disoproxil fumarate have comparable efficacy in achieving surrogate end points, including virologic response, and are equally recommended as first-line treatments for patients with chronic hepatitis B (CHB). However, it
Jonggi Choi, Hyo Jeong Kim, Jayoun Lee, Songhee Cho, M. Ko, Y. Lim   +5 more
semanticscholar   +1 more source

The antiviral drug tenofovir, an inhibitor of Pannexin-1-mediated ATP release, prevents liver and skin fibrosis by downregulating adenosine levels in the liver and skin. [PDF]

PLoS ONE, 2017
Fibrosing diseases are a leading cause of morbidity and mortality worldwide and, therefore, there is a need for safe and effective antifibrotic therapies.
Jessica L Feig, Aranzazu Mediero, Carmen Corciulo, Hailing Liu, Jin Zhang, Miguel Perez-Aso, Laura Picard, Tuere Wilder, Bruce Cronstein   +8 more
doaj   +1 more source

Preferred antiretroviral drugs for the next decade of scale up [PDF]

, 2012
Global commitments aim to provide antiretroviral therapy (ART) to 15 million people living with HIV by 2015, and recent studies have demonstrated the potential for widespread ART to prevent HIV transmission.
Andrieux-Meyer, Isabelle, Cahn, Pedro, Calmy, Alexandra, Clayden, Polly, Ford, Nathan, Goemaere, Eric, Katlama, Christine, Levin, Andrew, Lynch, Sharonann, Raguin, Gilles, Vitoria, Marco   +10 more
core   +4 more sources

Real-Time and Wireless Assessment of Adherence to Antiretroviral Therapy With Co-Encapsulated Ingestion Sensor in HIV-Infected Patients: A Pilot Study. [PDF]

, 2020
Adherence with antiretroviral therapy is important for preventing disease progression and HIV transmission. The co-encapsulated pill sensor system sends a signal through a cutaneous patch and allows real-time monitoring of pill ingestion. A 16-week pilot
Corado, Katya, Daar, Eric S, Dao, John, Fletcher, Courtney V, Guerrero, Mario, Liu, Honghu, Rosen, Marc I, Shen, Jie, Siqueiros, Lisa, Wang, Yan, Xiong, Di, Young, Todd   +11 more
core   +1 more source

Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials

Alimentary Pharmacology and Therapeutics
In two phase 3 studies, tenofovir alafenamide (TAF) showed non‐inferior efficacy versus tenofovir disoproxil fumarate (TDF), with more favourable renal and bone safety in patients with chronic hepatitis B (CHB).
María Buti, Young-Suk Lim, H. Chan, Kosh Agarwal, Patrick Marcellin, M. Brunetto, Wan-Long Chuang, H.L. Janssen, Scott Fung, Namiki Izumi, Maciej S. Jablkowski, D. Abdurakhmanov, F. Abramov, Hongyuan Wang, Irina Botros, Leland J. Yee, Roberto Mateo, J. Flaherty, Anu Osinusi, Calvin Q. Pan, X. Shalimar, W. Seto, Edward J. Gane   +22 more
semanticscholar   +1 more source

Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho [PDF]

, 2011
Article approval pendingLatest World Health Organization guidelines recommend shifting away from Stavudine (d4T)-based regimens due to severe side effects.
Bygrave, Helen, Cleary, Susan, Ford, Nathan, Gadot, Laurent, Goemaere, Eric, Hilderbrand, Katherine, Jouquet, Guillaume, Kranzer, Katharina, Lee, Janice, Makakole, Lipontso, Trivino, Laura, Vlahakis, Natalie   +11 more
core   +2 more sources